Q-omics provides the consensus-scored TAS2R20 profile across patient tissues and cancer cell-line models. TAS2R20 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAS2R20 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TAS2R20 RNA expression shows 19,925 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where TAS2R20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAS2R20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAS2R20 survival associations across molecular data types. TAS2R20 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAS2R20 RNA expression–survival associations across cancer types. High TAS2R20 expression shows unfavorable associations in KIRC, ACC, COAD and MESO, but favorable associations in BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAS2R20 RNA expression.
This table summarizes TAS2R20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TAS2R20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAS2R20 shows lower tumor expression in UCEC and higher tumor expression in KIRC, HNSC, LIHC, CHOL and PAAD. The KIRC box plot shows higher TAS2R20 RNA expression in tumor versus normal tissue (log2 FC = +0.308, t-test p < 0.001).
This table shows molecular features associated with TAS2R20 in patient tissues and cancer cell lines. In patient samples, TAS2R20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAS2R20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
